2023
NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024.
Abu-Rustum N, Yashar C, Arend R, Barber E, Bradley K, Brooks R, Campos S, Chino J, Chon H, Crispens M, Damast S, Fisher C, Frederick P, Gaffney D, Gaillard S, Giuntoli R, Glaser S, Holmes J, Howitt B, Lea J, Mantia-Smaldone G, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Podoll M, Rodabaugh K, Salani R, Schorge J, Siedel J, Sisodia R, Soliman P, Ueda S, Urban R, Wyse E, McMillian N, Aggarwal S, Espinosa S. NCCN Guidelines® Insights: Cervical Cancer, Version 1.2024. Journal Of The National Comprehensive Cancer Network 2023, 21: 1224-1233. PMID: 38081139, DOI: 10.6004/jnccn.2023.0062.Peer-Reviewed Original ResearchConceptsCervical cancerNCCN guidelinesNCCN Guidelines InsightsSystemic therapy recommendationsAdvanced cervical cancerMetastatic diseaseTreatment landscapeClinical outcomesDiagnostic workupHistopathologic classificationTherapy recommendationsCancerMolecular profileAspects of managementRecent updatesDiagnostic featuresGuidelinesWorkupStagingDiseaseRecurrentPathology
2021
NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021.
Abu-Rustum NR, Yashar CM, Bradley K, Campos SM, Chino J, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Diver E, Fisher CM, Frederick P, Gaffney DK, George S, Giuntoli R, Han E, Howitt B, Huh WK, Lea J, Mariani A, Mutch D, Nekhlyudov L, Podoll M, Remmenga SW, Reynolds RK, Salani R, Sisodia R, Soliman P, Tanner E, Ueda S, Urban R, Wethington SL, Wyse E, Zanotti K, McMillian NR, Motter AD. NCCN Guidelines® Insights: Uterine Neoplasms, Version 3.2021. Journal Of The National Comprehensive Cancer Network 2021, 19: 888-895. PMID: 34416706, DOI: 10.6004/jnccn.2021.0038.Peer-Reviewed Original Research
2020
NCCN Guidelines Insights: Cervical Cancer, Version 1.2020.
Abu-Rustum NR, Yashar CM, Bean S, Bradley K, Campos SM, Chon HS, Chu C, Cohn D, Crispens MA, Damast S, Fisher CM, Frederick P, Gaffney DK, Giuntoli R, Han E, Huh WK, Lurain Iii JR, Mariani A, Mutch D, Nagel C, Nekhlyudov L, Fader AN, Remmenga SW, Reynolds RK, Sisodia R, Tillmanns T, Ueda S, Urban R, Wyse E, McMillian NR, Motter AD. NCCN Guidelines Insights: Cervical Cancer, Version 1.2020. Journal Of The National Comprehensive Cancer Network 2020, 18: 660-666. PMID: 32502976, DOI: 10.6004/jnccn.2020.0027.Peer-Reviewed Original ResearchConceptsCervical cancerNCCN Guidelines InsightsSystemic therapy recommendationsTreatment of patientsHistopathologic classification systemNCCN guidelinesMetastatic diseaseDiagnostic workupEndocervical adenocarcinomaTherapy recommendationsPatientsCancerDiseaseRecent updatesClassification systemGuidelinesHPVAdenocarcinomaWorkupStagingRecurrent
2019
Outcomes of FIGO 2009 stage IB grade 2 or 3 endometrioid endometrial adenocarcinoma treated with adjuvant vaginal brachytherapy following comprehensive surgical staging
Hochreiter A, Kelly J, Young M, Litkouhi B, Black J, Stromberger C, Higgins S, Schwartz P, Damast S. Outcomes of FIGO 2009 stage IB grade 2 or 3 endometrioid endometrial adenocarcinoma treated with adjuvant vaginal brachytherapy following comprehensive surgical staging. Gynecologic Oncology 2019, 154: 287. DOI: 10.1016/j.ygyno.2019.04.674.Peer-Reviewed Original Research